Clinical trial
Alisertib (MLN8237) or Investigator's Choice in Patients With…
NCT01482962 · Millennium Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT01482962 |
|---|---|
| Title | Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma |
| Official title | A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma |
| Lead sponsor | Millennium Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma |
| Intervention type | Drug |
| Interventions | Alisertib, Pralatrexate, Gemcitabine, Romidepsin |
| Enrollment | 271 |
| Start date | Jun 11, 2012 |
| Primary completion | Jun 30, 2015 |
| Completion | Dec 18, 2017 |
| First posted | Dec 1, 2011 |
| Last update posted | Jul 31, 2018 |
| Countries | Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, Chile, Czechia, Denmark, Egypt, France and 19 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: